Filing Details
- Accession Number:
- 0001209191-19-059526
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-06 18:25:40
- Reporting Period:
- 2019-12-05
- Accepted Time:
- 2019-12-06 18:25:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1131146 | Stephen Davis | C/O Acadia Pharmaceuticals Inc. 3611 Valley Centre Drive, Ste. 300 San Diego CA 92130 | Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-12-05 | 150,000 | $19.65 | 152,954 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-12-05 | 81,585 | $52.82 | 71,369 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-05 | 40,159 | $52.09 | 31,210 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-05 | 28,256 | $51.32 | 2,954 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-12-05 | 150,000 | $0.00 | 150,000 | $19.65 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 300,000 | 2026-03-14 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 22, 2019.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.64 to $53.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.63 to $52.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.72 to $51.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 25% of the 600,000 shares originally subject to the stock option vested and became exercisable on March 15, 2017, and the remaining shares vest in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
